Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
18119 | 565 | 36.5 | 83% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
416 | 3 | NEUROENDOCRINE TUMORS//CARCINOID//SMALL CELL CARCINOMA | 28897 |
808 | 2 | RADIOIMMUNOTHERAPY//NUCLEAR MEDICINE AND BIOLOGY//ANTIBODY DRUG CONJUGATE | 12023 |
18119 | 1 | PRETARGETING//PRETARGETED RADIOIMMUNOTHERAPY//MOL MED IMMUNOL | 565 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PRETARGETING | authKW | 3086387 | 16% | 63% | 91 |
2 | PRETARGETED RADIOIMMUNOTHERAPY | authKW | 639985 | 3% | 79% | 15 |
3 | MOL MED IMMUNOL | address | 339595 | 5% | 23% | 27 |
4 | AVIDINOX | authKW | 216175 | 1% | 100% | 4 |
5 | RADIOIMMUNOTHERAPY | authKW | 187606 | 12% | 5% | 66 |
6 | GARDEN STATE CANC | address | 185776 | 3% | 18% | 19 |
7 | MULTISTEP TARGETING | authKW | 162131 | 1% | 100% | 3 |
8 | PRIT | authKW | 162131 | 1% | 100% | 3 |
9 | BISPECIFIC ANTIBODY | authKW | 145137 | 5% | 9% | 30 |
10 | ANTISENSE IMAGING | authKW | 144114 | 1% | 67% | 4 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Radiology, Nuclear Medicine & Medical Imaging | 5254 | 38% | 0% | 212 |
2 | Oncology | 1422 | 27% | 0% | 153 |
3 | Biochemical Research Methods | 1000 | 15% | 0% | 83 |
4 | Chemistry, Organic | 405 | 13% | 0% | 76 |
5 | Chemistry, Multidisciplinary | 196 | 15% | 0% | 83 |
6 | Medicine, Research & Experimental | 192 | 8% | 0% | 45 |
7 | Biochemistry & Molecular Biology | 180 | 19% | 0% | 106 |
8 | Pharmacology & Pharmacy | 178 | 13% | 0% | 72 |
9 | Chemistry, Medicinal | 49 | 4% | 0% | 20 |
10 | Hematology | 13 | 2% | 0% | 13 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOL MED IMMUNOL | 339595 | 5% | 23% | 27 |
2 | GARDEN STATE CANC | 185776 | 3% | 18% | 19 |
3 | UNIT 463 | 122821 | 1% | 45% | 5 |
4 | MOL PHARMACOL THER Y SERV | 121597 | 1% | 75% | 3 |
5 | ABT RADIOCHEM RADIOPHARMAKOL | 54044 | 0% | 100% | 1 |
6 | BOUVE HLTH SCI PHARMACEUT SCI | 54044 | 0% | 100% | 1 |
7 | CEA LRC | 54044 | 0% | 100% | 1 |
8 | CHEM BIOL PEPTIDES PROT | 54044 | 0% | 100% | 1 |
9 | COORDINATEUR GRP TRAVAIL | 54044 | 0% | 100% | 1 |
10 | CRCNAINSERMUMR892 | 54044 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOCONJUGATE CHEMISTRY | 47275 | 12% | 1% | 66 |
2 | JOURNAL OF NUCLEAR MEDICINE | 28398 | 13% | 1% | 73 |
3 | CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 25023 | 5% | 2% | 26 |
4 | NUCLEAR MEDICINE AND BIOLOGY | 16965 | 6% | 1% | 34 |
5 | ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS | 5265 | 1% | 2% | 4 |
6 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 4861 | 3% | 1% | 17 |
7 | NUCLEAR MEDICINE COMMUNICATIONS | 4198 | 3% | 0% | 18 |
8 | MOLECULAR IMAGING AND BIOLOGY | 3587 | 1% | 1% | 8 |
9 | CLINICAL CANCER RESEARCH | 3032 | 5% | 0% | 29 |
10 | CANCER RESEARCH | 1127 | 5% | 0% | 29 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PRETARGETING | 3086387 | 16% | 63% | 91 | Search PRETARGETING | Search PRETARGETING |
2 | PRETARGETED RADIOIMMUNOTHERAPY | 639985 | 3% | 79% | 15 | Search PRETARGETED+RADIOIMMUNOTHERAPY | Search PRETARGETED+RADIOIMMUNOTHERAPY |
3 | AVIDINOX | 216175 | 1% | 100% | 4 | Search AVIDINOX | Search AVIDINOX |
4 | RADIOIMMUNOTHERAPY | 187606 | 12% | 5% | 66 | Search RADIOIMMUNOTHERAPY | Search RADIOIMMUNOTHERAPY |
5 | MULTISTEP TARGETING | 162131 | 1% | 100% | 3 | Search MULTISTEP+TARGETING | Search MULTISTEP+TARGETING |
6 | PRIT | 162131 | 1% | 100% | 3 | Search PRIT | Search PRIT |
7 | BISPECIFIC ANTIBODY | 145137 | 5% | 9% | 30 | Search BISPECIFIC+ANTIBODY | Search BISPECIFIC+ANTIBODY |
8 | ANTISENSE IMAGING | 144114 | 1% | 67% | 4 | Search ANTISENSE+IMAGING | Search ANTISENSE+IMAGING |
9 | TUMOR PRETARGETING | 121597 | 1% | 75% | 3 | Search TUMOR+PRETARGETING | Search TUMOR+PRETARGETING |
10 | ANTIBODY PRETARGETING | 108087 | 0% | 100% | 2 | Search ANTIBODY+PRETARGETING | Search ANTIBODY+PRETARGETING |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WALTER, RB , PRESS, OW , PAGEL, JM , (2010) PRETARGETED RADIOIMMUNOTHERAPY FOR HEMATOLOGIC AND OTHER MALIGNANCIES.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. VOL. 25. ISSUE 2. P. 125-142 | 102 | 70% | 14 |
2 | LIU, GZ , HNATOWICH, DJ , (2008) A SEMIEMPIRICAL MODEL OF TUMOR PRETARGETING.BIOCONJUGATE CHEMISTRY. VOL. 19. ISSUE 11. P. 2095-2104 | 86 | 87% | 13 |
3 | GRUAZ-GUYON, A , RAGUIN, O , BARBET, J , (2005) RECENT ADVANCES IN PRETARGETED RADIOIMMUNOTHERAPY.CURRENT MEDICINAL CHEMISTRY. VOL. 12. ISSUE 3. P. 319-338 | 102 | 62% | 27 |
4 | BOERMAN, OC , VAN SCHAIJK, FG , OYEN, WJG , CORSTENS, FHM , (2003) PRETARGETED RADIOIMMUNOTHERAPY OF CANCER: PROGRESS STEP BY STEP.JOURNAL OF NUCLEAR MEDICINE. VOL. 44. ISSUE 3. P. 400-411 | 63 | 82% | 136 |
5 | GOLDENBERG, DM , SHARKEY, RM , PAGANELLI, G , BARBET, J , CHATAL, JF , (2006) ANTIBODY PRETARGETING ADVANCES CANCER RADIOIMMUNODETECTION AND RADIOIMMUNOTHERAPY.JOURNAL OF CLINICAL ONCOLOGY. VOL. 24. ISSUE 5. P. 823 -834 | 61 | 67% | 187 |
6 | KRAEBER-BODERE, F , ROUSSEAU, C , BODET-MILIN, C , FRAMPAS, E , FAIVRE-CHAUVET, A , RAUSCHER, A , SHARKEY, RM , GOLDENBERG, DM , CHATAL, JF , BARBET, J , (2015) A PRETARGETING SYSTEM FOR TUMOR PET IMAGING AND RADIOIMMUNOTHERAPY.FRONTIERS IN PHARMACOLOGY. VOL. 6. ISSUE . P. - | 38 | 73% | 5 |
7 | GOLDENBERG, DM , CHANG, CH , ROSSI, EA , MCBRIDE, WJ , SHARKEY, RM , (2012) PRETARGETED MOLECULAR IMAGING AND RADIOIMMUNOTHERAPY.THERANOSTICS. VOL. 2. ISSUE 5. P. 523-540 | 51 | 48% | 35 |
8 | CHANG, CH , SHARKEY, RM , ROSSI, EA , KARACAY, H , MCBRIDE, W , HANSEN, HJ , CHATAL, JF , BARBET, J , GOLDENBERG, DM , (2002) MOLECULAR ADVANCES IN PRETARGETING RADIOIMUNOTHERAPY WITH BISPECIFIC ANTIBODIES.MOLECULAR CANCER THERAPEUTICS. VOL. 1. ISSUE 7. P. 553-563 | 40 | 78% | 91 |
9 | SHARKEY, RM , CHANG, CH , ROSSI, EA , MCBRIDE, WJ , GOLDENBERG, DM , (2012) PRETARGETING: TAKING AN ALTERNATE ROUTE FOR LOCALIZING RADIONUCLIDES.TUMOR BIOLOGY. VOL. 33. ISSUE 3. P. 591-600 | 36 | 67% | 13 |
10 | SAKAHARA, H , SAGA, T , (1999) AVIDIN-BIOTIN SYSTEM FOR DELIVERY OF DIAGNOSTIC AGENTS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 37. ISSUE 1-3. P. 89-101 | 47 | 68% | 68 |
Classes with closest relation at Level 1 |